Stem Cells http://www.peprotech.com/
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tahara, T.
Right arrow Articles by Kato, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tahara, T.
Right arrow Articles by Kato, T.
Stem Cells, Vol. 16, No. 1, 54-60, January 1998
© 1998 AlphaMed Press

Neutralization of Biological Activity and Inhibition of Receptor Binding by Antibodies Against Human Thrombopoietin

Tomoyuki Tahara, Tomoaki Kuwaki, Atsushi Matsumoto, Haruhiko Morita, Hiroshi Watarai, Yoshimasa Inagaki, Hideya Ohashi, Kinya Ogami, Hiroshi Miyazaki, Takashi Kato

Pharmaceutical Research Laboratory, Kirin Brewery Co., Ltd., Takasaki, Gunma, Japan

Key Words. Thrombopoietin • Neutralizing antibody • Peptide antibody • c-Mpl ligand • Active domain • ELISA

Dr. Takashi Kato, Pharmaceutical Research Laboratory, Kirin Brewery Co., Ltd., 3 Miyahara-cho, Takasaki, Gunma 370-12, Japan.

Thrombopoietin (TPO) is a recently isolated cytokine that primarily regulates megakaryocytopoiesis and thrombopoiesis. We recently reported the development of a variety of antibodies (Abs) to synthetic peptides of human (h)TPO and to recombinant human TPO (rhTPO). In this study, we characterized the Abs and mapped immunologically distinct areas of the molecule. Among the five different antipeptide polyclonal Abs, only one, raised against synthetic peptide D8 to Q28, neutralized the TPO-dependent growth of FDCP-2 cells expressing human Mpl (FDCP-hMpl5 cells). One out of seven anti-rhTPO monoclonal Abs, designated as TN1, also showed neutralizing activity. TN1 was found to be specifically reactive with two proteolytic fragments, residues S1 to R117 and A60 to K122 of hTPO, indicating that the epitope(s) of TN1 is localized in residues A60 to R117 of the molecule. These two neutralizing Abs inhibited the binding of biotinylated rhTPO to FDCP-hMpl5 cells. On the other hand, the other Abs, which reacted with five polypeptides of S47 to D62, L108 to A126, N172 to A190, S262 to T284, and P306 to G332 of hTPO, did not show either the neutralizing activity or the ability to inhibit the binding of biotinylated rhTPO to the cell surface hMpl. These findings indicate that two regions, residues D8 to Q28 and A60 to R117 of hTPO, may contain the domains associated with its receptor, c-Mpl. These Abs characterized here are valuable for studying the structural analysis and the biological function of hTPO mediated by its receptor.




This article has been cited by other articles:


Home page
Proc. Natl. Acad. Sci. USAHome page
M. D. Feese, T. Tamada, Y. Kato, Y. Maeda, M. Hirose, Y. Matsukura, H. Shigematsu, T. Muto, A. Matsumoto, H. Watarai, et al.
Structure of the receptor-binding domain of human thrombopoietin determined by complexation with a neutralizing antibody fragment
PNAS, February 17, 2004; 101(7): 1816 - 1821.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
H. M. Linden and K. Kaushansky
The Glycan Domain of Thrombopoietin (TPO) Acts in trans to Enhance Secretion of the Hormone and Other Cytokines
J. Biol. Chem., September 13, 2002; 277(38): 35240 - 35247.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
N. Shiroshita, M. Musashi, K. Sakurada, K. Kimura, Y. Tsuda, S. Ota, H. Iwasaki, T. Miyazaki, T. Kato, H. Miyazaki, et al.
Involvement of Protein Kinase C-epsilon in Signal Transduction of Thrombopoietin in Enhancement of Interleukin-3-Dependent Proliferation of Primitive Hematopoietic Progenitors
J. Pharmacol. Exp. Ther., June 1, 2001; 297(3): 868 - 875.
[Abstract] [Full Text]


Home page
Stem CellsHome page
T. Kato, A. Matsumoto, K. Ogami, T. Tahara, H. Morita, and H. Miyazaki
Native Thrombopoietin: Structure and Function
Stem Cells, September 1, 1998; 16(5): 322 - 328.
[Abstract] [Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
STEM CELLS THE ONCOLOGIST CME ALPHAMED PRESS JOURNALS

Copyright © 1998 by AlphaMed Press.